Workflow
盈利预期修正
icon
Search documents
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
ZACKS· 2025-05-19 14:56
Core Viewpoint - Karyopharm Therapeutics (KPTI) shows significant upside potential with a mean price target of $33.07, indicating a 521.6% increase from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $8 to $67.47, with a standard deviation of $23.37, suggesting a high variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 50.4%, while the highest suggests an upside of 1168.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising KPTI's earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 4.9% rise in the Zacks Consensus Estimate for the current year [12] - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]
Flexible Solutions International Inc. (FSI) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-15 23:16
分组1 - Flexible Solutions International Inc. (FSI) reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of $0.05, and compared to earnings of $0.04 per share a year ago, representing an earnings surprise of -140% [1] - The company posted revenues of $7.47 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 26.73%, and down from year-ago revenues of $9.23 million [2] - Over the last four quarters, FSI has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] 分组2 - The stock has gained approximately 19.9% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $11.61 million, and for the current fiscal year, it is $0.30 on revenues of $48.78 million [7] - The Zacks Industry Rank for Chemical - Specialty is currently in the bottom 42% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% of ranked industries [8]
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-15 23:01
Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.45 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $1.63 per share a year ago [1] - The company posted revenues of $3.02 million for the quarter, missing the Zacks Consensus Estimate by 18.49%, and down from $3.42 million in the same quarter last year [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates [2] Stock Performance - Vivos Therapeutics shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The current Zacks Rank for Vivos Therapeutics is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $4.2 million, and for the current fiscal year, it is -$1.54 on revenues of $16.6 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]
Cava Group (CAVA) Surpasses Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-15 22:36
Cava Group (CAVA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.14%. A quarter ago, it was expected that this Mediterranean restaurant chain would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the last four qua ...
LightPath Technologies, Inc. (LPTH) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2025-05-15 22:36
Company Performance - LightPath Technologies reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, and compared to a loss of $0.07 per share a year ago, indicating an earnings surprise of -100% [1] - The company posted revenues of $9.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.21%, and this represents an increase from year-ago revenues of $7.7 million [2] - Over the last four quarters, LightPath Technologies has surpassed consensus EPS estimates only once [2] Stock Performance - LightPath Technologies shares have declined approximately 24.9% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $12.93 million, and for the current fiscal year, it is -$0.18 on revenues of $38.04 million [7] Industry Outlook - The Electronics - Miscellaneous Components industry, to which LightPath Technologies belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LightPath Technologies' stock performance [5]
PLBY Group, Inc. (PLBY) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-15 22:26
Group 1: Financial Performance - PLBY Group reported a quarterly loss of $0.10 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.23 per share a year ago [1] - The company posted revenues of $28.88 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 8.15%, compared to revenues of $28.32 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $28.55 million, and for the current fiscal year, it is -$1.59 on revenues of $119.9 million [7] Group 2: Market Performance and Outlook - PLBY Group shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The estimate revisions trend for PLBY Group is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Leisure and Recreation Products industry, to which PLBY Group belongs, is currently ranked in the bottom 11% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8]
Virgin Galactic (SPCE) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-15 22:21
Core Insights - Virgin Galactic reported a quarterly loss of $2.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $2.23, but an improvement from a loss of $5 per share a year ago [1] - The company posted revenues of $0.46 million for the quarter, exceeding the Zacks Consensus Estimate by 15.25%, but down from $1.99 million year-over-year [2] - Virgin Galactic shares have declined approximately 39.6% year-to-date, contrasting with a 0.2% gain in the S&P 500 [3] Financial Performance - The earnings surprise for the latest quarter was -6.73%, while the previous quarter saw a positive surprise of 29.72% with an actual loss of $2.53 against an expected loss of $3.60 [1][2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates twice [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$2.10 on revenues of $0.4 million, and for the current fiscal year, it is -$8.72 on revenues of $2.3 million [7] - The estimate revisions trend for Virgin Galactic is currently favorable, leading to a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - The Aerospace - Defense industry, to which Virgin Galactic belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]
LM Funding America, Inc. (LMFA) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-15 13:21
分组1 - LM Funding America, Inc. reported a quarterly loss of $1.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.65, and compared to a loss of $0.84 per share a year ago, indicating a significant earnings surprise of -61.54% [1] - The company posted revenues of $2.37 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 15.32%, and down from $4.75 million in the same quarter last year [2] - The stock has underperformed the market, losing about 23.3% since the beginning of the year, while the S&P 500 has gained 0.2% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.45 on revenues of $2.5 million, and for the current fiscal year, it is -$2.56 on revenues of $9.8 million [7] - The Zacks Industry Rank for Financial - Miscellaneous Services is in the top 39% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]
Stantec (STN) Tops Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-14 23:25
Stantec (STN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.53%. A quarter ago, it was expected that this engineering firm would post earnings of $0.69 per share when it actually produced earnings of $0.79, delivering a surprise of 14.49%.Over the last four quarters, the company h ...
Usio Inc (USIO) Reports Q1 Loss, Misses Revenue Estimates
ZACKS· 2025-05-14 22:15
分组1 - Usio Inc reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.04, representing an earnings surprise of -125% [1] - The company posted revenues of $22.01 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.66%, compared to year-ago revenues of $20.32 million [2] - Over the last four quarters, Usio has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates [2] 分组2 - The stock has gained approximately 8.2% since the beginning of the year, outperforming the S&P 500's gain of 0.1% [3] - The current consensus EPS estimate for the coming quarter is $0.01 on revenues of $22.97 million, and $0.16 on revenues of $94.69 million for the current fiscal year [7] - The Financial Transaction Services industry, to which Usio belongs, is currently in the top 32% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]